Unmet Needs of Effective Advanced Systemic Therapies in Moderate-to-Severe Atopic Dermatitis Patients in the TARGET-DERM AD Registry.

Challenge

A substantial proportion of patients with moderate-to-severe AD are eligible for but never receive advanced systemic therapies, yet the real-world scale of this treatment gap—and the longitudinal outcomes of those who do and do not receive AST—had not been characterized in a large North American registry spanning both adolescents and adults.

Solution

The TARGET-DERM AD registry was used to stratify patients into four subgroups (AST-naïve, AST-retrospective, AST-prospective, and AST-failed) and characterize demographics, clinical outcomes, and longitudinal response trajectories within each, providing a comprehensive real-world picture of the advanced therapy landscape in moderate-to-severe AD.

Impact

Demonstrating that a third of eligible patients remain AST-naïve and that substantial proportions of AST-treated patients fail to achieve adequate control establishes the unmet need evidence base for new advanced therapies and supports regulatory and payer arguments for next-generation AD treatments.